Last $8.91 USD
Change Today -0.03 / -0.34%
Volume 551.5K
SUPN On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

supernus pharmaceuticals inc (SUPN) Snapshot

Open
$8.92
Previous Close
$8.94
Day High
$8.99
Day Low
$8.80
52 Week High
07/2/14 - $11.47
52 Week Low
12/23/13 - $6.85
Market Cap
382.5M
Average Volume 10 Days
480.3K
EPS TTM
$-0.03
Shares Outstanding
42.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SUPERNUS PHARMACEUTICALS INC (SUPN)

supernus pharmaceuticals inc (SUPN) Related Bloomberg News

View More Bloomberg News

supernus pharmaceuticals inc (SUPN) Related Businessweek News

No Related Businessweek News Found

supernus pharmaceuticals inc (SUPN) Details

Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. Its products include Oxtellar XR and Trokendi XR, which are neurology products used for the treatment of epilepsy; SPN-810, a molindone hydrochloride that has completed Phase IIb clinical trials for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder (ADHD); and SPN-812, which has completed Phase IIa clinical trials for the treatment of ADHD. The company is also developing SPN-809 as a once-daily product candidate for the treatment of depression. It markets its products through wholesalers and pharmaceutical distributors. Supernus Pharmaceuticals, Inc. was founded in 2005 and is based in Rockville, Maryland.

235 Employees
Last Reported Date: 03/21/14
Founded in 2005

supernus pharmaceuticals inc (SUPN) Top Compensated Officers

Founder, Chief Executive Officer, President, ...
Total Annual Compensation: $462.9K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $308.9K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $314.8K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $156.2K
Compensation as of Fiscal Year 2013.

supernus pharmaceuticals inc (SUPN) Key Developments

Supernus Announces Paragraph IV ANDA Filing for Oxtellar XR(R)

Supernus Pharmaceuticals, Inc. announced that on December 9, 2014 the company received a 'Paragraph IV Notice Letter' from TWi Pharmaceuticals, Inc. advising Supernus of the filing by TWi of an Abbreviated New Drug Application seeking approval for oxcarbazepine extended-release tablets. Supernus is currently reviewing the details of this Notice Letter and intends to vigorously enforce its intellectual property rights relating to Oxtellar XR. The product is currently protected by four issued patents that expire no earlier than 2027.

Supernus Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Revises Revenue Guidance for the Full Year 2014

Supernus Pharmaceuticals, Inc. Reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported total revenue of $52,488,000 against $1,257,000 a year ago. Operating income was $29,167,000 against operating loss of $17,175,000 a year ago. Net profit was $27,858,000 against net loss of $24,096,000 a year ago. Basic and diluted income per share was $0.39 against $0.78 diluted per share a year ago. Adjusted net loss - non-GAAP was $2,042,000 against $19,943,000 a year ago. The improvement in net income is driven primarily by increased revenue associated with higher prescription volumes from Oxtellar XR and Trokendi XR coupled with the $30 million payment from Healthcare Royalty Partners to acquire a portion of the royalty rights for Orenitram. For the nine months, the company reported total revenue of $91,244,000 against $1,684,000 a year ago. Operating income was $19,500,000 against operating loss of $50,563,000 a year ago. Net profit was $15,516,000 against net loss of $69,867,000 a year ago. Basic and diluted income per share was $0.13 against $2.26 diluted per share a year ago. Adjusted net loss - non-GAAP was $14,007,000 against $56,013,000 a year ago. The company raises revenue guidance from approximately $105 million to a range of $115 million to $118 million for 2014. The company is reducing its cash burn guidance for the year from as range of $5 million to $10 million to approximately $5 million, and raising its guidance for year-end cash and marketable securities from a range of $75 million to $85 million to approximately $85 million. The company anticipates achieving cash flow break even by year end and being profitable in 2015.

Supernus Pharmaceuticals, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 02:30 PM

Supernus Pharmaceuticals, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 02:30 PM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SUPN:US $8.91 USD -0.03

SUPN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $58.88 USD +1.20
Cosmo Pharmaceuticals SpA SFr.148.80 CHF -0.30
Depomed Inc $16.24 USD +0.52
Durect Corp $0.81 USD -0.06
Veloxis Pharmaceuticals A/S kr1.17 DKK -0.04
View Industry Companies
 

Industry Analysis

SUPN

Industry Average

Valuation SUPN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.8x
Price/Book 5.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SUPERNUS PHARMACEUTICALS INC, please visit www.supernus.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.